- December 13, 2018
H. pylori drug achieves positive results in phase 3 study
Talicia, a novel drug for the treatment of Helicobacter pylori, achieved positive top-line results in a phase 3 study, according to a press release from RedHill Biopharma, the manufacturer.
- December 13, 2018
Orchard Therapeutics to Build Out Gene Therapy Manufacturing Site in Fremont, CA
Orchard Therapeutics said it will build out a gene therapy manufacturing facility in Fremont, CA, that will employ 100 people and expand its manufacturing capabilities to support plans for an expanded pipeline.
- December 13, 2018
Check-Cap wins conditional IDE approval for C-Scan pilot study
Check-Cap (NSDQ:CHEK) said today it won conditional approval from the FDA for its investigational device exemption application to launch a pilot study of its C-Scan system. The Israel-based company’s C-Scan system is designed as an alternative to standard colon cancer screening methods.
- December 13, 2018
Orchard Expects to Hire 100, Expands Gene Therapy Manufacturing in Bay Area
Orchard Therapeutics is expanding its physical footprint in California. The U.K.-based company signed a long-term lease to build out a gene therapy manufacturing facility in Fremont, Calif. The 150,000-square-foot facility will add to the company’s presence in the Bay Area.
- December 11, 2018
Robust Pipeline for Treatments for Diabetic Eye Disease with Dr. Patrik De Haes Oxurion
Dr. Patrik De Haes, CEO, Oxurion discusses the need for new treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.
- December 11, 2018
Transcranial Magnetic Brain Stimulation to Treat Depression and OCD: Interview with Stanford’s Dr. Nolan Williams
- December 7, 2018
Orchard’s Gene Therapy for Rare Immune Disease Works for Over a Year
A single dose of a gene therapy developed by Orchard Therapeutics can restore immune function for at least a year in patients with X-linked chronic granulomatous disease (X-CGD).
- December 6, 2018
Alkahest doses first patient in Phase II Parkinson’s drug trial
Alkahest has dosed the first subject in a Phase II clinical trial of GRF6021 to treat Parkinson’s disease associated with mild cognitive impairment or dementia.
